Landiolol in the treatment of the intraoperative supraventricular tachycardia: a multicenter, randomized, double-blind, placebo-controlled study
Abstract Background Supraventricular tachycardia during the induction of anesthesia may carry a higher risk. Study objective The aim of this study was to evaluate efficacy and safety of intravenous landiolol in Chinese patients with intraoperative supraventricular tachycardia during anesthesia. Desi...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical anesthesia 2015-03, Vol.27 (2), p.120-128 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 128 |
|---|---|
| container_issue | 2 |
| container_start_page | 120 |
| container_title | Journal of clinical anesthesia |
| container_volume | 27 |
| creator | Xiao, Jie He, Ping Zou, Qiaoqun Zhao, Yanhua Xue, Zhanggang Deng, Xiaoming Li, Shitong Guo, Qunlian Tao, Guocai Yang, Tiande Lang, Zhixun He, Jia Wang, Xiangrui |
| description | Abstract Background Supraventricular tachycardia during the induction of anesthesia may carry a higher risk. Study objective The aim of this study was to evaluate efficacy and safety of intravenous landiolol in Chinese patients with intraoperative supraventricular tachycardia during anesthesia. Design A randomized, double-blind, placebo-controlled, parallel-group, multicenter, phase 2 study. Setting Eight sites of Chinese hospitals. Patients Men and women aged 18 to 70 years with the intraoperative supraventricular tachycardia (heart rate [HR], ≥ 100 beats/min) or the supraventricular tachycardia outside of the sinus tachycardia lasting more than 1 minute. Interventions Patients received landiolol or placebo—0.125 mg kg − 1 min − 1 (1 minute) loading→0.04 mg kg − 1 min − 1 (10 minutes) continuous. Measurements The proportion of patients receiving rescue medication (esmolol) when the reduction of HR did not exceed 10% after intravenous landiolol for 5 minutes. Other secondary efficacy end points include HR, blood pressure, rate pressure product, and electrocardiogram; the improvement of supraventricular tachycardia; the time it takes for the decrease of the HR to reach more than 10%; and the time it takes for the HR to reach < 100 beats/min. Main results Efficacy and safety were evaluated for 240 patients who received study drug. Lower proportions of patients received rescue medication in the landiolol group (7.63%) compared with that in the placebo group (80.33%) ( P < .0001). Suppression of HR and rate pressure product was generally more potent( P < .0001), and higher proportions of patients improved supraventricular tachycardia ( P < .0001) in the landiolol group. The most frequent adverse event was hypotension. Conclusion Intravenous landiolol (loading dose of 0.125 mg/kg) may effectively control intraoperative supraventricular tachycardia during anesthesia. It inhibited the increases in HR during the induction of anesthesia. The effect of landiolol on blood pressure was minimal without decreasing diastolic blood pressure and with the minor reduction of systolic blood pressure (ClinicalTrials.gov number, ChiCTR-TRC-12003021). |
| doi_str_mv | 10.1016/j.jclinane.2014.07.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1662428802</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0952818014003250</els_id><sourcerecordid>1662428802</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-592e5e34b853298ecd6ff49ff7d6b81a6dd8ab5450ff6558a2f3b626ba1daf593</originalsourceid><addsrcrecordid>eNqFks9u1DAQxiMEokvhFSpLXDg0wXZiJ-GAQFX5I63EAThbjj1WHZw42M5Ky1PwyHXYFqReOFn2_ObzzHxTFBcEVwQT_nqsRuXsLGeoKCZNhdsK4_pRsSNdW5cNo_3jYod7RsuOdPiseBbjiDHOAfK0OKOsqRuGya74vZeztt55h-yM0g2gFECmCeaEvPnzYOcUpF8gyGQPgOK6BHnI8WDV6mRASaqbo5JBW_kGSTStLlmV4xAuUcjqfrK_QF8i7dfBQTnksvNtcVLB4Evls5J3DjSKadXH58UTI12EF3fnefH9w_W3q0_l_svHz1fv96VqGEkl6ykwqJuhYzXtO1CaG9P0xrSaDx2RXOtODiw3aQxnrJPU1AOnfJBES8P6-rx4ddJdgv-5QkxislGBc3mkfo2CcE4b2nWYZvTlA3T0a5hzdRtFCGk4bzPFT5QKPsYARizBTjIcBcFi80yM4t4zsXkmcCuyZznx4k5-HSbQf9PuTcrAuxMAeR4HC0FEZWFWoG0AlYT29v9_vH0gsVFWSfcDjhD_9SMiFVh83TZnWxzS5GzKcH0LJzLDbg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1661114667</pqid></control><display><type>article</type><title>Landiolol in the treatment of the intraoperative supraventricular tachycardia: a multicenter, randomized, double-blind, placebo-controlled study</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Xiao, Jie ; He, Ping ; Zou, Qiaoqun ; Zhao, Yanhua ; Xue, Zhanggang ; Deng, Xiaoming ; Li, Shitong ; Guo, Qunlian ; Tao, Guocai ; Yang, Tiande ; Lang, Zhixun ; He, Jia ; Wang, Xiangrui</creator><creatorcontrib>Xiao, Jie ; He, Ping ; Zou, Qiaoqun ; Zhao, Yanhua ; Xue, Zhanggang ; Deng, Xiaoming ; Li, Shitong ; Guo, Qunlian ; Tao, Guocai ; Yang, Tiande ; Lang, Zhixun ; He, Jia ; Wang, Xiangrui</creatorcontrib><description>Abstract Background Supraventricular tachycardia during the induction of anesthesia may carry a higher risk. Study objective The aim of this study was to evaluate efficacy and safety of intravenous landiolol in Chinese patients with intraoperative supraventricular tachycardia during anesthesia. Design A randomized, double-blind, placebo-controlled, parallel-group, multicenter, phase 2 study. Setting Eight sites of Chinese hospitals. Patients Men and women aged 18 to 70 years with the intraoperative supraventricular tachycardia (heart rate [HR], ≥ 100 beats/min) or the supraventricular tachycardia outside of the sinus tachycardia lasting more than 1 minute. Interventions Patients received landiolol or placebo—0.125 mg kg − 1 min − 1 (1 minute) loading→0.04 mg kg − 1 min − 1 (10 minutes) continuous. Measurements The proportion of patients receiving rescue medication (esmolol) when the reduction of HR did not exceed 10% after intravenous landiolol for 5 minutes. Other secondary efficacy end points include HR, blood pressure, rate pressure product, and electrocardiogram; the improvement of supraventricular tachycardia; the time it takes for the decrease of the HR to reach more than 10%; and the time it takes for the HR to reach < 100 beats/min. Main results Efficacy and safety were evaluated for 240 patients who received study drug. Lower proportions of patients received rescue medication in the landiolol group (7.63%) compared with that in the placebo group (80.33%) ( P < .0001). Suppression of HR and rate pressure product was generally more potent( P < .0001), and higher proportions of patients improved supraventricular tachycardia ( P < .0001) in the landiolol group. The most frequent adverse event was hypotension. Conclusion Intravenous landiolol (loading dose of 0.125 mg/kg) may effectively control intraoperative supraventricular tachycardia during anesthesia. It inhibited the increases in HR during the induction of anesthesia. The effect of landiolol on blood pressure was minimal without decreasing diastolic blood pressure and with the minor reduction of systolic blood pressure (ClinicalTrials.gov number, ChiCTR-TRC-12003021).</description><identifier>ISSN: 0952-8180</identifier><identifier>EISSN: 1873-4529</identifier><identifier>DOI: 10.1016/j.jclinane.2014.07.003</identifier><identifier>PMID: 25434501</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject><![CDATA[Adrenergic beta-1 Receptor Antagonists - administration & dosage ; Adult ; Aged ; Anesthesia & Perioperative Care ; Anti-Arrhythmia Agents - administration & dosage ; Anti-Arrhythmia Agents - adverse effects ; Anti-Arrhythmia Agents - therapeutic use ; Blood Pressure - drug effects ; Cardiac arrhythmia ; Double-Blind Method ; Drug Administration Schedule ; Drug therapy ; Drug Therapy, Combination ; Efficacy ; Electrocardiography ; Esmolol ; Female ; Heart attacks ; Heart Rate - drug effects ; Humans ; Hypotension - chemically induced ; Infusions, Intravenous ; Intraoperative Complications - drug therapy ; Intraoperative Complications - physiopathology ; Intraoperative supraventricular tachycardia ; Landiolol ; Male ; Middle Aged ; Morpholines - administration & dosage ; Morpholines - adverse effects ; Morpholines - therapeutic use ; Pain Medicine ; Propanolamines - administration & dosage ; Safety ; Tachycardia, Supraventricular - drug therapy ; Tachycardia, Supraventricular - physiopathology ; Treatment Outcome ; Urea - administration & dosage ; Urea - adverse effects ; Urea - analogs & derivatives ; Urea - therapeutic use ; Young Adult]]></subject><ispartof>Journal of clinical anesthesia, 2015-03, Vol.27 (2), p.120-128</ispartof><rights>Elsevier Inc.</rights><rights>2014 Elsevier Inc.</rights><rights>Copyright © 2014 Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-592e5e34b853298ecd6ff49ff7d6b81a6dd8ab5450ff6558a2f3b626ba1daf593</citedby><cites>FETCH-LOGICAL-c451t-592e5e34b853298ecd6ff49ff7d6b81a6dd8ab5450ff6558a2f3b626ba1daf593</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1661114667?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25434501$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xiao, Jie</creatorcontrib><creatorcontrib>He, Ping</creatorcontrib><creatorcontrib>Zou, Qiaoqun</creatorcontrib><creatorcontrib>Zhao, Yanhua</creatorcontrib><creatorcontrib>Xue, Zhanggang</creatorcontrib><creatorcontrib>Deng, Xiaoming</creatorcontrib><creatorcontrib>Li, Shitong</creatorcontrib><creatorcontrib>Guo, Qunlian</creatorcontrib><creatorcontrib>Tao, Guocai</creatorcontrib><creatorcontrib>Yang, Tiande</creatorcontrib><creatorcontrib>Lang, Zhixun</creatorcontrib><creatorcontrib>He, Jia</creatorcontrib><creatorcontrib>Wang, Xiangrui</creatorcontrib><title>Landiolol in the treatment of the intraoperative supraventricular tachycardia: a multicenter, randomized, double-blind, placebo-controlled study</title><title>Journal of clinical anesthesia</title><addtitle>J Clin Anesth</addtitle><description>Abstract Background Supraventricular tachycardia during the induction of anesthesia may carry a higher risk. Study objective The aim of this study was to evaluate efficacy and safety of intravenous landiolol in Chinese patients with intraoperative supraventricular tachycardia during anesthesia. Design A randomized, double-blind, placebo-controlled, parallel-group, multicenter, phase 2 study. Setting Eight sites of Chinese hospitals. Patients Men and women aged 18 to 70 years with the intraoperative supraventricular tachycardia (heart rate [HR], ≥ 100 beats/min) or the supraventricular tachycardia outside of the sinus tachycardia lasting more than 1 minute. Interventions Patients received landiolol or placebo—0.125 mg kg − 1 min − 1 (1 minute) loading→0.04 mg kg − 1 min − 1 (10 minutes) continuous. Measurements The proportion of patients receiving rescue medication (esmolol) when the reduction of HR did not exceed 10% after intravenous landiolol for 5 minutes. Other secondary efficacy end points include HR, blood pressure, rate pressure product, and electrocardiogram; the improvement of supraventricular tachycardia; the time it takes for the decrease of the HR to reach more than 10%; and the time it takes for the HR to reach < 100 beats/min. Main results Efficacy and safety were evaluated for 240 patients who received study drug. Lower proportions of patients received rescue medication in the landiolol group (7.63%) compared with that in the placebo group (80.33%) ( P < .0001). Suppression of HR and rate pressure product was generally more potent( P < .0001), and higher proportions of patients improved supraventricular tachycardia ( P < .0001) in the landiolol group. The most frequent adverse event was hypotension. Conclusion Intravenous landiolol (loading dose of 0.125 mg/kg) may effectively control intraoperative supraventricular tachycardia during anesthesia. It inhibited the increases in HR during the induction of anesthesia. The effect of landiolol on blood pressure was minimal without decreasing diastolic blood pressure and with the minor reduction of systolic blood pressure (ClinicalTrials.gov number, ChiCTR-TRC-12003021).</description><subject>Adrenergic beta-1 Receptor Antagonists - administration & dosage</subject><subject>Adult</subject><subject>Aged</subject><subject>Anesthesia & Perioperative Care</subject><subject>Anti-Arrhythmia Agents - administration & dosage</subject><subject>Anti-Arrhythmia Agents - adverse effects</subject><subject>Anti-Arrhythmia Agents - therapeutic use</subject><subject>Blood Pressure - drug effects</subject><subject>Cardiac arrhythmia</subject><subject>Double-Blind Method</subject><subject>Drug Administration Schedule</subject><subject>Drug therapy</subject><subject>Drug Therapy, Combination</subject><subject>Efficacy</subject><subject>Electrocardiography</subject><subject>Esmolol</subject><subject>Female</subject><subject>Heart attacks</subject><subject>Heart Rate - drug effects</subject><subject>Humans</subject><subject>Hypotension - chemically induced</subject><subject>Infusions, Intravenous</subject><subject>Intraoperative Complications - drug therapy</subject><subject>Intraoperative Complications - physiopathology</subject><subject>Intraoperative supraventricular tachycardia</subject><subject>Landiolol</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Morpholines - administration & dosage</subject><subject>Morpholines - adverse effects</subject><subject>Morpholines - therapeutic use</subject><subject>Pain Medicine</subject><subject>Propanolamines - administration & dosage</subject><subject>Safety</subject><subject>Tachycardia, Supraventricular - drug therapy</subject><subject>Tachycardia, Supraventricular - physiopathology</subject><subject>Treatment Outcome</subject><subject>Urea - administration & dosage</subject><subject>Urea - adverse effects</subject><subject>Urea - analogs & derivatives</subject><subject>Urea - therapeutic use</subject><subject>Young Adult</subject><issn>0952-8180</issn><issn>1873-4529</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFks9u1DAQxiMEokvhFSpLXDg0wXZiJ-GAQFX5I63EAThbjj1WHZw42M5Ky1PwyHXYFqReOFn2_ObzzHxTFBcEVwQT_nqsRuXsLGeoKCZNhdsK4_pRsSNdW5cNo_3jYod7RsuOdPiseBbjiDHOAfK0OKOsqRuGya74vZeztt55h-yM0g2gFECmCeaEvPnzYOcUpF8gyGQPgOK6BHnI8WDV6mRASaqbo5JBW_kGSTStLlmV4xAuUcjqfrK_QF8i7dfBQTnksvNtcVLB4Evls5J3DjSKadXH58UTI12EF3fnefH9w_W3q0_l_svHz1fv96VqGEkl6ykwqJuhYzXtO1CaG9P0xrSaDx2RXOtODiw3aQxnrJPU1AOnfJBES8P6-rx4ddJdgv-5QkxislGBc3mkfo2CcE4b2nWYZvTlA3T0a5hzdRtFCGk4bzPFT5QKPsYARizBTjIcBcFi80yM4t4zsXkmcCuyZznx4k5-HSbQf9PuTcrAuxMAeR4HC0FEZWFWoG0AlYT29v9_vH0gsVFWSfcDjhD_9SMiFVh83TZnWxzS5GzKcH0LJzLDbg</recordid><startdate>20150301</startdate><enddate>20150301</enddate><creator>Xiao, Jie</creator><creator>He, Ping</creator><creator>Zou, Qiaoqun</creator><creator>Zhao, Yanhua</creator><creator>Xue, Zhanggang</creator><creator>Deng, Xiaoming</creator><creator>Li, Shitong</creator><creator>Guo, Qunlian</creator><creator>Tao, Guocai</creator><creator>Yang, Tiande</creator><creator>Lang, Zhixun</creator><creator>He, Jia</creator><creator>Wang, Xiangrui</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20150301</creationdate><title>Landiolol in the treatment of the intraoperative supraventricular tachycardia: a multicenter, randomized, double-blind, placebo-controlled study</title><author>Xiao, Jie ; He, Ping ; Zou, Qiaoqun ; Zhao, Yanhua ; Xue, Zhanggang ; Deng, Xiaoming ; Li, Shitong ; Guo, Qunlian ; Tao, Guocai ; Yang, Tiande ; Lang, Zhixun ; He, Jia ; Wang, Xiangrui</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-592e5e34b853298ecd6ff49ff7d6b81a6dd8ab5450ff6558a2f3b626ba1daf593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adrenergic beta-1 Receptor Antagonists - administration & dosage</topic><topic>Adult</topic><topic>Aged</topic><topic>Anesthesia & Perioperative Care</topic><topic>Anti-Arrhythmia Agents - administration & dosage</topic><topic>Anti-Arrhythmia Agents - adverse effects</topic><topic>Anti-Arrhythmia Agents - therapeutic use</topic><topic>Blood Pressure - drug effects</topic><topic>Cardiac arrhythmia</topic><topic>Double-Blind Method</topic><topic>Drug Administration Schedule</topic><topic>Drug therapy</topic><topic>Drug Therapy, Combination</topic><topic>Efficacy</topic><topic>Electrocardiography</topic><topic>Esmolol</topic><topic>Female</topic><topic>Heart attacks</topic><topic>Heart Rate - drug effects</topic><topic>Humans</topic><topic>Hypotension - chemically induced</topic><topic>Infusions, Intravenous</topic><topic>Intraoperative Complications - drug therapy</topic><topic>Intraoperative Complications - physiopathology</topic><topic>Intraoperative supraventricular tachycardia</topic><topic>Landiolol</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Morpholines - administration & dosage</topic><topic>Morpholines - adverse effects</topic><topic>Morpholines - therapeutic use</topic><topic>Pain Medicine</topic><topic>Propanolamines - administration & dosage</topic><topic>Safety</topic><topic>Tachycardia, Supraventricular - drug therapy</topic><topic>Tachycardia, Supraventricular - physiopathology</topic><topic>Treatment Outcome</topic><topic>Urea - administration & dosage</topic><topic>Urea - adverse effects</topic><topic>Urea - analogs & derivatives</topic><topic>Urea - therapeutic use</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xiao, Jie</creatorcontrib><creatorcontrib>He, Ping</creatorcontrib><creatorcontrib>Zou, Qiaoqun</creatorcontrib><creatorcontrib>Zhao, Yanhua</creatorcontrib><creatorcontrib>Xue, Zhanggang</creatorcontrib><creatorcontrib>Deng, Xiaoming</creatorcontrib><creatorcontrib>Li, Shitong</creatorcontrib><creatorcontrib>Guo, Qunlian</creatorcontrib><creatorcontrib>Tao, Guocai</creatorcontrib><creatorcontrib>Yang, Tiande</creatorcontrib><creatorcontrib>Lang, Zhixun</creatorcontrib><creatorcontrib>He, Jia</creatorcontrib><creatorcontrib>Wang, Xiangrui</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical anesthesia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xiao, Jie</au><au>He, Ping</au><au>Zou, Qiaoqun</au><au>Zhao, Yanhua</au><au>Xue, Zhanggang</au><au>Deng, Xiaoming</au><au>Li, Shitong</au><au>Guo, Qunlian</au><au>Tao, Guocai</au><au>Yang, Tiande</au><au>Lang, Zhixun</au><au>He, Jia</au><au>Wang, Xiangrui</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Landiolol in the treatment of the intraoperative supraventricular tachycardia: a multicenter, randomized, double-blind, placebo-controlled study</atitle><jtitle>Journal of clinical anesthesia</jtitle><addtitle>J Clin Anesth</addtitle><date>2015-03-01</date><risdate>2015</risdate><volume>27</volume><issue>2</issue><spage>120</spage><epage>128</epage><pages>120-128</pages><issn>0952-8180</issn><eissn>1873-4529</eissn><abstract>Abstract Background Supraventricular tachycardia during the induction of anesthesia may carry a higher risk. Study objective The aim of this study was to evaluate efficacy and safety of intravenous landiolol in Chinese patients with intraoperative supraventricular tachycardia during anesthesia. Design A randomized, double-blind, placebo-controlled, parallel-group, multicenter, phase 2 study. Setting Eight sites of Chinese hospitals. Patients Men and women aged 18 to 70 years with the intraoperative supraventricular tachycardia (heart rate [HR], ≥ 100 beats/min) or the supraventricular tachycardia outside of the sinus tachycardia lasting more than 1 minute. Interventions Patients received landiolol or placebo—0.125 mg kg − 1 min − 1 (1 minute) loading→0.04 mg kg − 1 min − 1 (10 minutes) continuous. Measurements The proportion of patients receiving rescue medication (esmolol) when the reduction of HR did not exceed 10% after intravenous landiolol for 5 minutes. Other secondary efficacy end points include HR, blood pressure, rate pressure product, and electrocardiogram; the improvement of supraventricular tachycardia; the time it takes for the decrease of the HR to reach more than 10%; and the time it takes for the HR to reach < 100 beats/min. Main results Efficacy and safety were evaluated for 240 patients who received study drug. Lower proportions of patients received rescue medication in the landiolol group (7.63%) compared with that in the placebo group (80.33%) ( P < .0001). Suppression of HR and rate pressure product was generally more potent( P < .0001), and higher proportions of patients improved supraventricular tachycardia ( P < .0001) in the landiolol group. The most frequent adverse event was hypotension. Conclusion Intravenous landiolol (loading dose of 0.125 mg/kg) may effectively control intraoperative supraventricular tachycardia during anesthesia. It inhibited the increases in HR during the induction of anesthesia. The effect of landiolol on blood pressure was minimal without decreasing diastolic blood pressure and with the minor reduction of systolic blood pressure (ClinicalTrials.gov number, ChiCTR-TRC-12003021).</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>25434501</pmid><doi>10.1016/j.jclinane.2014.07.003</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0952-8180 |
| ispartof | Journal of clinical anesthesia, 2015-03, Vol.27 (2), p.120-128 |
| issn | 0952-8180 1873-4529 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1662428802 |
| source | MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
| subjects | Adrenergic beta-1 Receptor Antagonists - administration & dosage Adult Aged Anesthesia & Perioperative Care Anti-Arrhythmia Agents - administration & dosage Anti-Arrhythmia Agents - adverse effects Anti-Arrhythmia Agents - therapeutic use Blood Pressure - drug effects Cardiac arrhythmia Double-Blind Method Drug Administration Schedule Drug therapy Drug Therapy, Combination Efficacy Electrocardiography Esmolol Female Heart attacks Heart Rate - drug effects Humans Hypotension - chemically induced Infusions, Intravenous Intraoperative Complications - drug therapy Intraoperative Complications - physiopathology Intraoperative supraventricular tachycardia Landiolol Male Middle Aged Morpholines - administration & dosage Morpholines - adverse effects Morpholines - therapeutic use Pain Medicine Propanolamines - administration & dosage Safety Tachycardia, Supraventricular - drug therapy Tachycardia, Supraventricular - physiopathology Treatment Outcome Urea - administration & dosage Urea - adverse effects Urea - analogs & derivatives Urea - therapeutic use Young Adult |
| title | Landiolol in the treatment of the intraoperative supraventricular tachycardia: a multicenter, randomized, double-blind, placebo-controlled study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T01%3A17%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Landiolol%20in%20the%20treatment%20of%20the%20intraoperative%20supraventricular%20tachycardia:%20a%20multicenter,%20randomized,%20double-blind,%20placebo-controlled%20study&rft.jtitle=Journal%20of%20clinical%20anesthesia&rft.au=Xiao,%20Jie&rft.date=2015-03-01&rft.volume=27&rft.issue=2&rft.spage=120&rft.epage=128&rft.pages=120-128&rft.issn=0952-8180&rft.eissn=1873-4529&rft_id=info:doi/10.1016/j.jclinane.2014.07.003&rft_dat=%3Cproquest_cross%3E1662428802%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1661114667&rft_id=info:pmid/25434501&rft_els_id=1_s2_0_S0952818014003250&rfr_iscdi=true |